KIORA PHARMACEUTICALS, INC. Gain (Loss) on Extinguishment of Debt
KIORA PHARMACEUTICALS, INC. (KPRX) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2023-03-23
- KIORA PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-09-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-06-30 was $278.19K.
- KIORA PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2014-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- KIORA PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2021 was $278.19K.
- KIORA PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2020 was $0.00.
- KIORA PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-23 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $278.19K derived: sum of 3 quarters · filed 2023-03-23 | $278.19K 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $278.19K derived: sum of 2 quarters · filed 2022-11-09 | $278.19K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $278.19K 10-Q · filed 2022-08-12 | $278.19K 10-Q · filed 2022-08-12 | ||
| 2020-12-31 | $0.00 10-K/A · filed 2022-07-07 | |||
| 2015-12-31 | $0.00 10-K · filed 2016-03-30 | |||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-12 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $240.00K derived: sum of 2 quarters · filed 2016-03-30 | $240.00K 10-K · filed 2016-03-30 | |
| 2014-09-30 | $240.00K 10-Q · filed 2015-11-12 | $240.00K 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | -$200.76K 10-Q · filed 2015-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |